SAN DIEGO, Aug. 24 /PRNewswire/ — Pfenex Inc. and Cedarlane
today announced that they have entered into a non-exclusive
distribution agreement. Cedarlane will market and distribute high
value reagent proteins produced by Pfenex to researchers in Canada
and the United States. Among the products initially distributed
will be vaccine carrier proteins such as CRM197 and Cholera Toxin B
and cell culture related growth factors including G-CSF and
Interferon beta 1-b. New products which are developed by Pfenex
will be added to the Cedarlane catalogue upon launch.
“We are pleased to establish this distribution relationship with
Cedarlane,” stated Patrick K. Lucy, Vice President, Business
Development at Pfenex Inc. “Leveraging the Pfenex Expression
Technology™ platform, we are now producing and making
available complex reagent proteins to meet the needs of the biotech
R&D and clinical development community. As Pfenex grows its
reagent proteins business, we welcome the opportunity to work with
world class distributors such as Cedarlane to enable placing Pfenex
products in the hands of life science researchers around the
world.”
“CEDARLANE is proud to add Pfenex Inc. products to its extensive
portfolio,” said John Course, CEDARLANE Vice President. “Canadian
scientists have an even greater opportunity to consolidate their
ordering from a long list of high-quality suppliers of scientific
reagents.” Key components of the CEDARLANE mission are to provide
quality products, assure the highest in customer satisfaction and
respond to the dynamic needs of every research community.
About Pfenex Inc.
Pfenex Inc. is a protein production company leveraging the
unique and powerful Pfenex Expression Technology™ platform
based on the microorganism, Pseudomonas fluorescens, for the
production of research proteins, reagent proteins, biosimilars and
innovator biopharmaceuticals. For more information please visit
